Ra Pharmctl (RARX) Getting Favorable Press Coverage, Report Shows

Media stories about Ra Pharmctl (NASDAQ:RARX) have been trending positive on Friday, Accern reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ra Pharmctl earned a coverage optimism score of 0.27 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.4280768982186 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Shares of Ra Pharmctl (RARX) traded down 1.78% during mid-day trading on Friday, reaching $13.21. 165,777 shares of the company traded hands. Ra Pharmctl has a 52-week low of $12.05 and a 52-week high of $24.12. The stock’s market capitalization is $298.66 million. The stock’s 50 day moving average is $14.79 and its 200 day moving average is $14.79.

Ra Pharmctl (NASDAQ:RARX) last issued its earnings results on Wednesday, August 9th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.06). On average, analysts anticipate that Ra Pharmctl will post ($2.31) earnings per share for the current year.

RARX has been the topic of a number of research reports. Zacks Investment Research lowered shares of Ra Pharmctl from a “hold” rating to a “sell” rating in a report on Wednesday, July 12th. Jefferies Group LLC reaffirmed a “buy” rating and set a $25.00 price target on shares of Ra Pharmctl in a report on Friday, July 14th. Finally, Royal Bank Of Canada initiated coverage on shares of Ra Pharmctl in a report on Thursday, September 14th. They set an “outperform” rating and a $21.00 price target for the company. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $24.00.

TRADEMARK VIOLATION WARNING: This story was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.dispatchtribunal.com/2017/10/27/ra-pharmctl-rarx-getting-favorable-press-coverage-accern-reports.html.

Ra Pharmctl Company Profile

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

Insider Buying and Selling by Quarter for Ra Pharmctl (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmctl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmctl Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply